NCT04231565View on ClinicalTrials.gov

Nucleoside (Acid) Analogues Treatment in Patients With Normal ALT and Positive HBVDNA.

NARecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

June 4, 2020

Primary Completion Date

June 1, 2024

Study Completion Date

July 1, 2027

Conditions
Hepatitis B Virus
Interventions
DRUG

Tenofovir alafenamide Fumarate

Patients would receive treatment of oral Tenofovir alafenamide Fumarate（TAF）once per day.

Trial Locations (1)

510630

RECRUITING

Third Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Third Affiliated Hospital, Sun Yat-Sen University

OTHER